Pacesetter, Inc.

Other

Siemens-pacesetter, Inc.

Packsetter, Inc.

Paul A Levine

Gene A Bornzin

Jason A Sholder

Brian M Mann

Xing Pei

Mark W Kroll

Melinda A Endaya

Joseph J Florio

Kenneth Valikai

Robert E Smith, Jr

Eric Falkenberg

Lisa P Weinberg

Euljoon Park

Eliot L Ostrow

Xiaoyi Min

Eric Steven Fain

Timothy A Fayram

Laurence S Sloman

Armando M Cappa

Heidi Hellman

Allan R Schwartz

Harold C Schloss

James L Duncan

Rohan More

Gregory C Bevan

Arndt Godau

Bruce L Wilkoff

Jeff Zimmer

Diane Crawford

Andrew E Epstein

Kelly Hobart McClure

Anne Margaret Pianca

Taraneh Ghaffari Farazi

Gabriel A Mouchawar

John W Poore

Jeffery D Snell

Edward Karst

Peter Boileau

James D Causey, Iii

Wenbo Hou

Brian Jeffrey Wenzel

Allen J Keel

Anders Björling

J Christopher Moulder

Sergiu Silvian

Rose Province

Balakrishnan Shankar

Siew Bee Er

G Neal Kay

Josh Reiss

Scott Patrick Simon

Kenneth R McNeil, Ii

Hanbiao Wang

Bonian Dai

Corey L Brown

Jeffrey D Snell

J Kelly Fox

James B Hamilton

Derrick W Reed

Matthew Whitlock

Malcolm Clarke

J Jeffrey Barlow

Amdt Godau

Qiuju Huang

Ken Bruhns

Kristen M Levine

Mark R Myers

An exemplary method includes performing a capture threshold assessment using a bipolar electrode configuration, deciding if capture occurred for a maximum energy value of the capture threshold assessment and, if capture did not occur, then performing a lead impedance test for the lead associated with the bipolar electrode configuration. Such a test may aim to detect an insulation defect and/or a conductor defect. Other exemplary methods, devices, systems, etc., are also disclosed.

Capture threshold and lead condition analysis

An implantable medical device is provided for detecting transportless ventricular rhythm of a heart lacking atrial transport and comprises a housing, sensors configured to be located proximate to a heart, a sensing module to sense cardiac signals representative of a rhythm originating from the heart and a rhythm detection module. The rhythm detection module determines a change in AV association and identifies a potential ventricular complex with loss of atrial transport (VCLAT) based on the change in AV association.

Method and system for detecting and treating junctional rhythms

A triggered mode pacing system enables dual chamber sensing. The system also determines whether a cardiac event is initially sensed in a first cardiac chamber or a second cardiac chamber. The system then triggers an output to the second cardiac chamber in response to sensing the cardiac event in the first cardiac chamber when the cardiac event was determined to have been initially sensed in the first cardiac chamber.

Triggered mode pacing for cardiac resynchronization therapy

An implanted device is equipped with a flag that indicates to a remote monitoring unit that an event such as a patient medical emergency or device failure has occurred. The remote monitoring unit is configured in some embodiments to maintain a low power communication link with the implanted device when they are within range. When the flag indicates an event has occurred, the remote monitoring unit quickly downloads sensed data collected by the implanted device and transfers it over a network so that it can be utilized by a medical practitioner. The remote monitoring unit is further configured in some embodiments to query the implanted device at regular intervals. The remote monitoring unit may read a subset of the data stored by the implanted device and, based on that data, determine whether to complete a full or partial download.

Remote follow-up automaticity with intelligent data download restrictions

Systems and methods are provided for use by implantable medical devices equipped to deliver multi-site left ventricular (MSLV) pacing. MSLV is associated with a relatively long post-ventricular atrial blanking (PVAB) period that might limit the detection of pathologic rapid organized atrial tachycardias (OAT). In one example, MSLV cardiac resynchronization therapy (CRT) pacing is delivered within a tracking mode. A possible atrial tachycardia is detected based on the atrial rate exceeding an atrial tachycardia assessment rate (ATAR) threshold. The device then switches to single-site LV pacing, thereby effectively shortening the PVAB to detect additional atrial events that might otherwise be obscured, and thereby permitting the device to more reliably distinguish organized atrial tachycardias (such as atrial flutter) from sinus tachycardia. The device may also employ an automatic mode switch (AMS) threshold that is set higher than the ATAR threshold for use in switching from tracking modes to nontracking modes.

Systems and methods for use by an implantable medical device for controlling multi-site CRT pacing in the presence of atrial tachycardia

Systems and methods are provided for use by implantable medical devices equipped to deliver multi-site left ventricular (MSLV) pacing. Sequential MSLV is associated with a relatively long post-ventricular atrial blanking (PVAB) period that might limit the detection of pathologic rapid organized atrial tachycardias (OAT). In one example, sequential MSLV cardiac resynchronization therapy (CRT) pacing is delivered within a tracking mode. A possible atrial tachycardia is detected based on the atrial rate exceeding an atrial tachycardia assessment rate (ATAR) threshold. The device then switches to either single-site LV pacing or simultaneous MSLV pacing, thereby effectively shortening the PVAB to detect additional atrial events that might otherwise be obscured, and thereby permitting the device to more reliably distinguish OATs (such as atrial flutter) from sinus tachycardia. The device may also employ an automatic mode switch (AMS) threshold set higher than the ATAR threshold for use in switching from tracking modes to nontracking modes.

A device, such as an implantable cardiac device, and method for switching between arrhythmia prevention modes is disclosed. The method includes monitoring an electrocardiogram (EGM) of the heart, determining whether the heart is in a normal sinus rhythm or in an abnormal rhythm, delivering pacing pulses at a first rate to either an atrium or a ventricle when the heart is in a normal sinus rhythm, and delivering pacing pulses to a ventricle at a second rate when the heart is in an abnormal rhythm, such as an atrial arrhythmia. The first rate is selected to minimize the occurrence of premature ventricular contractions, and the second rate is selected to both minimize the occurrence of premature ventricular contractions and minimize the occurrence of premature conducted beats.

Method and device for switching between arrhythmia prevention modes

An implantable cardiac stimulation device and associated method perform a true or blanking period ventricular undersensing detection algorithm in response to ventricular loss of capture not associated with fusion or a change in capture threshold. The test identifies an originating cause of loss of capture, which may be ventricular undersensing of intrinsic R-waves or premature ventricular contractions occurring during a ventricular blanking period or atrial undersensing of P-waves resulting in blanking period ventricular undersensing. A corrective action is taken to reduce the likelihood of blanking period ventricular undersensing by automatically adjusting device operating parameters. The corrective action may include automatic adjustment of atrial sensitivity, shortening of the ventricular blanking period, or adjustment of the base stimulation rate. Minimizing the blanking period ventricular undersensing improves device performance by avoiding back-up stimulation and minimizing the risk of pacemaker competition-induced arrhythmias.

Multi-chamber ventricular automatic capture method and apparatus for minimizing true and blanking period induced ventricular undersensing

Certain embodiments of the present invention are related to an implantable monitoring device to monitor a patient's arterial blood pressure, where the device is configured to be implanted subcutaneously. The device includes subcutaneous (SubQ) electrodes and a plethysmography sensor. Additionally, the device includes an arterial blood pressure monitor configured to determine at least one value indicative of the patient's arterial blood pressure based on at least one detected predetermined feature of a SubQ ECG and at least one detected predetermined feature of a plethysmography signal. Alternative embodiments of the present invention are directed to a non-implantable monitoring device to monitor a patient's arterial blood pressure based on features of a surface ECG and a plethysmography signal obtained from a non-implanted sensor.

Standalone systemic arterial blood pressure monitoring device

Implantable systems, and methods for use therewith, for monitoring arterial blood pressure on a chronic basis are provided herein. A first signal indicative of electrical activity of a patient's heart, and a second signal indicative of mechanical activity of the patient's heart, are obtained using implanted electrodes and an implanted sensor. By measuring the times between various features of the first signal relative to features of the second signal, values indicative of systolic pressure and diastolic pressure can be determined. In specific embodiments, such features are used to determine a peak pulse arrival time (PPAT), which is used to determine the value indicative of systolic pressure. Additionally, a peak-to-peak amplitude at the maximum peak of the second signal, and the value indicative of systolic pressure, can be used to determine the value indicative of diastolic pressure.

Implantable systemic blood pressure measurement systems and methods

When a medical procedure is performed on a patient in whom an implantable medical device is implanted, the medical procedure may have undesired effects on the medical device, such as triggering a response that initiates therapy by the device that is unnecessary and potentially dangerous to the patient. Systems and methods may facilitate performing of such medical procedures on such patients by temporarily reprogramming the medical device, monitoring for one or more detectable characteristics associated with the medical procedure to be performed, and restoring normal programming of the device based on detection and/or lack of detection of the detectable characteristic(s).

Systems and methods for operating an implantable device for medical procedures

Growing community of inventors

Santa Clarita, CA, United States of America

Paul A Levine